Sanofi SA vs Teucrium Soybean Fund — how do they compare? Sanofi SA trades at $43.62 (market cap $104.30B), while Teucrium Soybean Fund trades at $25.05. The key difference: Sanofi SA pays a 5.55% dividend while Teucrium Soybean Fund pays none, and Teucrium Soybean Fund is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | SOYB | |
|---|---|---|
Market Cap | $104.30B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $52.34 | $26.28 |
52-Week Low | $41.33 | $21.46 |
Enterprise Value | $124.19B | — |
Dividend Yield | 5.55% | — |
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
SOYB trades at $25.05, down 0.48% on the day, with a bearish technical bias from moving averages and neutral oscillators. Key support and resistance cluster at $25. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights agricultural sector volatility from geopolitical tensions and trade developments.
The outlook is clouded by missing financial data, though China's $17 billion U.S. crop purchase pledge through 2028 (Zacks Investment Research, 2026-05-18) offers potential tailwinds. Risks include commodity price swings from Middle East conflicts (24/7 Wall Street, 2026-07-24) and opaque company performance.
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →